This Little-Known Biotech Stock Carries a Whopping $24 Price Target!

[Not long ago BSEM released its 2Q 2024 earnings results, which vastly exceeded estimates as revenue growth accelerated!]( The biotech space staged a comeback in late 2023 and early 2024 as Big Pharma tapped into takeovers again. In mid-July biotech tech stocks even hit a two-year high. One biotech company with exciting developments that may be going underfollowed is BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care. [According to Zacks, the average 12-month price target for BioStem Technologies, Inc. (BSEM) is $24.25! Why might Zack’s Small Cap Research be so bullish on BSEM with a $24.25 price target?]( Stellar financial results is one reason and another may be because a study published in a peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency and greater efficiency in general wound closure. Regenerative medicine is one of the most exciting arenas in medicine and BSEM is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. Last month BSEM announced that the Institutional Review Board (IRB) has approved a clinical study to evaluate its [Vendaje®]( product for diabetic foot ulcers (DFU), a key product in the company’s placental-derived allograft portfolio. This study aims to assess the efficacy of Vendaje compared to standard of care in diabetic patients with non-healing DFU’ s, providing critical data to support both patient outcomes and payer decisions. Diabetic Foot Ulcers are a significant risk for people with diabetes. According to the American Podiatric Medical Association (APMA), a leading resource for foot and ankle health, approximately 15 percent of people with diabetes develop foot ulcers. Of those 15 percent, six percent go on to be hospitalized due to infection or other ulcer-related complications. The risk to patients with diabetes is significant, as it is the leading cause of lower extremity amputations in the U.S. [Discover more about BSEM and its superior product for treating diabetic foot ulcers and how this could build shareholder value for investors!]( --------------------------------------------------------------- MarketMovingTrends c/o CLM Media LLC 45 South Park Place, #203 Morristown New Jersey 07936 USA [Unsubscribe]( | [Change Subscriber Options](